Drug Enforcement Administration Announces Date for Cannabis Hearing
The hearing concerning the federal scheduling of cannabis will potentially take place in December 2024.
Image | adobestock.com/Natalia
The Drug Enforcement Administration (DEA) announced a date for its hearing on the proposed rulemaking on the rescheduling of cannabis, according to an unpublished Public Inspection document posted on the Federal Register on August 26, 2024 (1). According to the notice, the hearing is scheduled to take place on December 2, 2024, at the DEA Hearing Facility in Arlington, Virginia. The four-page notice is scheduled to be officially published on August 29, 2024.
The notice, signed by DEA Administrator Anne Milgram, outlined the purpose of the upcoming hearing. “DEA is committed to conducting a transparent proceeding,” it stated. “Regarding the methods of public access, DEA will provide updates on the DEA website, https://www.dea.gov. In accordance with 21 U.S.C. 811 and 812, the purpose of the hearing is to ‘receiv[e] factual evidence and expert opinion regarding’ whether marijuana should be transferred to schedule III of the list of controlled substances.”
It also explained how to contribute opinions and information to the hearing. “Interested persons desiring to participate in this hearing must provide written notice of desired participation as set out below, on or before [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION],” and provided contact information and requirements for the notices of intent. Milgram will determine the participants and designate a presiding officer for the hearing.
The document also provided context for the hearing, starting with the May 21, 2024 Notice of Proposed Rulemaking to reschedule cannabis to a schedule III substance, noting its currently accepted medical use, which was affirmed by the Department of Health and Human Services in January 2024. A public hearing period began afterwards and resulted in over 40,000 comments.
Shares of some cannabis companies dropped on the day the DEA notice was posted (2). Some news sources have noted that the hearing will take place about a month after the presidential election.
References
- Department of Justice, Schedules of Controlled Substances: Rescheduling of Marijuana. Office of the Federal Register. https://www.federalregister.gov/public-inspection/2024-19370/schedules-of-controlled-substances-rescheduling-of-marijuana (accessed August 28, 2024).
- Reuters, Pot stocks fall as US DEA pushes cannabis reclassification hearing to December. https://www.reuters.com/markets/us/pot-stocks-fall-us-dea-pushes-cannabis-reclassification-hearing-december-2024-08-27/ (accessed August 28, 2024).
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
